Larry Ming Cheung Chow

Title: Innovations in Cancer Treatment by Larry Ming Cheung Chow

Introduction

Larry Ming Cheung Chow is a notable inventor based in Hong Kong, CN. He has made significant contributions to the field of cancer research, particularly in developing compounds that modulate multidrug resistance (MDR) in cancer cells. With a total of 2 patents, his work is paving the way for more effective cancer therapies.

Latest Patents

One of his latest patents focuses on alkyne-, azide-, and triazole-containing flavonoids as modulators for multidrug resistance in cancers. This innovative research led to the construction of a triazole bridged flavonoid dimer compound library through the cycloaddition reaction of flavonoid-containing azides and alkynes. The resulting compounds were screened for their ability to reverse MDR in various overexpressed cell lines, demonstrating promising activity against P-gp, MRP1, and BCRP-mediated drug resistance. The compounds exhibited varying levels of selectivity for different transporters and were categorized as mono-selective, dual-selective, and multi-selective modulators. Notably, some compounds showed EC50 values at or below 10 nM in BCRP-overexpressed cell lines, indicating their potential for selective inhibition of the BCRP transporter.

Career Highlights

Larry has worked with prestigious institutions such as The Hong Kong Polytechnic University and McGill University. His research has significantly advanced the understanding of how to combat drug resistance in cancer treatment, making him a key figure in this area of study.

Collaborations

Larry has collaborated with notable colleagues, including Tak Hang Chan and Kin Fai Chan, contributing to the collective effort in cancer research and innovation.

Conclusion

Larry Ming Cheung Chow's innovative work in developing flavonoid-based compounds represents a significant advancement in the fight against cancer. His contributions are crucial for improving treatment outcomes for patients facing multidrug resistance.